BOSTON, MA — In personalized antigen discovery, the hard part is no longer producing a mountain of candidates. The hard part is shrinking that mountain without losing the few signals that matter.

MyAntigen’s latest platform work focuses on that narrowing problem: connecting DNA change, RNA expression, tumor specificity, and biological plausibility into a shorter, cleaner manifest that a research team can actually use.

The aim is not to make discovery feel simple. It is to make the next experimental step feel obvious.

BOSTON, MA — A mutation can look compelling on paper and still be biologically quiet. That is why tumor RNA is becoming central to how we think about antigen priority.

For MyAntigen, RNA is not a decorative layer added at the end. It is a voting system. Candidates that are tumor-specific, expressed, and traceable rise; candidates that are elegant but silent fall.

The result is a manifest that better reflects what a tumor is actually presenting as an immunologic problem, not just what appears in a variant table.

BOSTON, MA — The word “manifest” sounds logistical, but in neoantigen discovery it can be philosophical. It is the place where noisy biology becomes a set of decisions.

Our view is that a good manifest should not merely rank candidates. It should preserve the reasoning: where each signal came from, why it survived filtering, and what confidence should follow it into the next stage.

That traceability is what lets collaborators move faster without turning the process into a black box.

BOSTON, MA — Sequencing creates abundance. Biology creates constraints. The danger is confusing the first for the second.

MyAntigen’s pipeline is being built around a simple discipline: every candidate should earn its place. Tumor specificity, expression evidence, and prioritization logic all have to survive together.

The practical payoff is a cleaner starting point for teams that would rather spend scarce experimental energy on candidates with a better reason to exist.

BOSTON, MA — A discovery platform has failed if its final output requires a second translation meeting before anyone can act on it.

That is why MyAntigen is treating the build-ready manifest as a product, not an afterthought. The goal is to hand research partners a concise, ordered, defensible set of candidates that connects directly to downstream design work.

In other words: fewer mysterious spreadsheets, more useful groceries.